THE PREVALENCE OF RHUPUS SYNDROME IN A MONOCONCEN TRIC TERTIARY REFERRAL COHORT
Silvia Grazetta Foddai, Elena Rubini, Massimo Radin, Irene Cecchi, Daniela Rossi, Savino Sciascia, Dario Roccatolesi. University of Turin, Turin, Italy

Background: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are two systemic chronic autoimmune diseases characterised by a wide spectrum of clinical and immune-pathological features. In clinical practice, the concept of Overlap Syndrome is defined when the two diseases coexist in the same patient. Rhupus syndrome is a rare clinical condition, characterized by overlap of SLE and RA. However, it is still subject to debate whether the syndrome should be considered a distinctive entity or an aggressive form of SLE. To date, the estimated prevalence of rhupus is unknown.

Objectives: To evaluate the prevalence of patients with rhupus syndrome in our tertiary care center.

Methods: We chart-reviewed all patients with a diagnosis of SLE[1] or RA[2], based on the current ACR classification criteria, who presented to our outpatient clinic rheumatology unit. Clinical and laboratory data were retrospectively collected from patient notes. Diagnosis were systematically analyzed by two independent reviewers (SGF and ER). Disagreements were resolved by consensus; if consensus could not be achieved, a third party (SS) would provide an assessment of eligibility.

Results: One-hundred eighty-two patients with a diagnosis of SLE and 253 patients of RA, were identified. Out of 182 SLE and 253 RA cases analysed, only 2 patients fulfilled rhupus criteria. The estimated prevalence in our cohort was 0.46% (2/437).

In Figure 1 are illustrated the clinical manifestations of SLE (Panel A; Malar rash) and RA (radiograph-documented erosive polyarthritis) of the two patients.

Additionally, we identified 7 patients (1.61% of the total cohort) that only partially fulfilled both criteria for SLE and RA. In detail, 1 patient (0.23%) manifested with an overlap of clinical manifestations of SLE and RA, while 1 patient had an overlap of both laboratory criteria. Two patients (0.46%) presented with clinical criteria of RA and laboratory criteria for SLE and RA and 3 patients (0.69%) with clinical criteria of SLE and laboratory criteria for SLE and RA.

Patient’s selection is resumed in Figure 2.

Table 1:

<table>
<thead>
<tr>
<th>ANA</th>
<th>anti-dsDNA</th>
<th>RF (U/ml)</th>
<th>anti-APCs (U/ml)</th>
<th>Articular involvement</th>
<th>SLE extra-articular manifestations</th>
<th>Immunosuppressive treatment undergone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>1:320</td>
<td>Positive</td>
<td>(IF)</td>
<td>Homogeneous pattern</td>
<td>Erosions of MTF and ulnar deviation of the wrists</td>
<td>leukopenia, malar rash</td>
</tr>
<tr>
<td>Patient 2</td>
<td>1:160</td>
<td>Positive</td>
<td>(IF)</td>
<td>Granular pattern</td>
<td>Loss of ICs, CMCs and MCPs joint space and bilateral MCP joint erosions (2nd-4th)</td>
<td>Myelitis, leukopenia, malar rash, oral ulcers</td>
</tr>
</tbody>
</table>

Conclusion: The prevalence of rhupus observed in our study was relatively low (0.46%). However, we identified up to 1.6% of patients partially fulfilling a diagnosis of rhupus. Rhupus syndrome is a rare and aggressive clinical condition and further prospective studies and an harmonization of classification criteria are highly needed.

REFERENCES

Disclosure of Interests: None declared


AB1268 VASCULAR INVOLVEMENT IN BEHÇET’S DISEASE : ABOUT 67 CASES
Aya Fraj, Raja Elamri, wafa garbouj, Zainab Alaya, Rim Khalfallah, Heyfa Tounsi, Imen Chaabane. Mohamed Tahir Maamouri Hospital, internal medicine department, Nabeul, Tunisia

Background: Behçet’s disease (BD) is a systemic vasculitis which ethiopathogenesis still poorly understood.

Vascular involvement is one of the major causes of mortality and morbidity in this disease. It occupies a special place in the cardiovascular pathologies because of its venous and arterial tropism all confounded caliber but also because of its pejorative prognosis as well on the functional level as vital.

Objectives: Our goal was to present the various venous and arterial manifestations of BD, their epidemiological, clinical, evolutionary and therapeutic characteristics.

Methods: This is a retrospective study over a period of 9 years [2009-2018] that enrolled 87 patients who met the international criteria for Behçet’s disease. The characteristics of vascular involvement were studied.

Results: Twenty-two patients had vascular involvement (25%). There are 17 men and 5 women (sex ratio H/F=3,4), mean age at diagnosis of angi Behçet 39 years [22 years-63 years]. The vascular lesions were indicative of the disease in 17 cases (77%), and for the other 5 patients, the mean time to onset of vascular disease compared with the diagnosis of BD was 2 years.

Figure 1

<table>
<thead>
<tr>
<th>Patient</th>
<th>ANA anti-dsDNA</th>
<th>RF (U/ml)</th>
<th>anti-APCs (U/ml)</th>
<th>Articular involvement</th>
<th>SLE extra-articular manifestations</th>
<th>Immunosuppressive treatment undergone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>1:320</td>
<td>Positive</td>
<td>(IF)</td>
<td>Homogeneous pattern</td>
<td>Erosions of MTF and ulnar deviation of the wrists</td>
<td>leukopenia, malar rash</td>
</tr>
<tr>
<td>Patient 2</td>
<td>1:160</td>
<td>Positive</td>
<td>(IF)</td>
<td>Granular pattern</td>
<td>Loss of ICs, CMCs and MCPs joint space and bilateral MCP joint erosions (2nd-4th)</td>
<td>Myelitis, leukopenia, malar rash, oral ulcers</td>
</tr>
</tbody>
</table>
Venous thrombosis involved 20 patients (90%). They were deep in 16 patients, superficial in one patient and superficial and deep in 3 patients. It was recurrent in 14 patients. The most common site of deep vein thrombosis was the lower limbs (n=17). The others had unusual sites: inferior vena cava thrombosis (n = 3), superior vena cava thrombosis (n = 2), sub-hepatic vein (n=1) and upper limb thrombosis (n = 1). Pulmonary embolism was noted in one case.

Arterial damage involved 4 patients (20%) divided into arterial aneurysms (3 cases) and arterial thromboses (2 cases). The locations were divided as follows: lower extremity arteries in 2 cases, upper limb arteries in one case, pulmonary artery in 2 cases and abdominal aorta in one case. Lower limb ischemia had occurred in one patient.

Two patients (10%) had mixed vascular, arterial and venous involvement, confirming the multiple and ubiquitous nature of angio-Behçet.

The treatment was based on colchicine, anticoagulants and corticosteroids in venous thromboses. Immunosuppressive therapy was started in 4 patients in front of the unusual site.

In arterial cases, corticosteroids in combination with immunosuppressant were prescribed. Flattening of the aneurysm was indicated in 2 cases with simple operative follow-up.

Conclusion: Behçet disease (BD) is very common in the Mediterranean basin, mainly affects the 30-year-old man. This systemic disease is characterized by oral aphthosis, genital ulcers and systemic involvement including ocular, gastrointestinal, neurological, and vessels that make the severity of the disease.

All types of vessels, regardless of size and seat, may be affected, with venous tropism.

Our study has just supported current literature data regarding the extensive and recurrent venous thrombosis during MB. The seriousness of this venous involvement lies in the involvement of the cavernous veins and in pulmonary embolism.

Arterial damage, such as thrombosis and/or aneurysm, is rare but maybe life-threatening.

Early diagnosis, intensive and appropriate treatment, regular follow-up and the involvement of a multidisciplinary team including internists, vascular surgeons and radiologists are key to better management of patients with angio-Behçet.

Our study illustrates the frequency and significance of vascular involvement in BD.

Disclosure of Interests: None declared


AB1269 RISK FACTORS ASSOCIATED WITH PERIPHERAL NEUROPATHY (PN) IN ANCA-ASSOCIATED VASCULITIS (AAV):

Violeta Higuera Ortiz1, Luis Humberto Silvera Torre2, Antonio Villa Romero2, Luis Felipe Flores-Salazar3, IMSS, Mexico City, Mexico; 2Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico; 3Faculty of Medicine, UNAM, Mexico City, Mexico; 4Instituto Nacional de Enfermedades Respiratorias, Primary Systemic Vasculitides Clinic, Mexico City, Mexico

Background: Few studies have reported on the risk factors associated with PN in AAV. Vascultic PN in AAV has been associated with male sex, arthritis, cutaneous, mucous membranes, and ENT manifestations of vasculitis. PN can lead to life quality impairment, as only 35% of the patients with PN have complete symptoms resolution within 6 months. Few studies have reported on the risk factors associated with PN in AAV.

Objectives: Along with describing the prevalence of incidence of PN in our cohort, we undertook this study to identify the risk factors associated with PN in AAV.

Methods: From 153 AAV patients (defined according to the EMA algorithm), 97 were eligible (complete data and no exclusion criteria -diabetes mellitus, axial disc disease, malignancies, herpetic neuralgia, other comorbidities). Clinical, electromyographic (EMG) and histopathological data were recorded. According to the presence (cases) or absence (controls) of clinical data for PN descriptive analysis is reported as means ± SD or medians (interquartile range-IQR). Categorical variables are reported as percentages. Sample size was estimated using Fishers exact test to compare proportions differences. To estimate PN predictors, bivariate and multivariate models to establish hazard ratios [HR] were built and analysed with Cox regression.

Results: Thirty-two (33%) patients (19-GPA, 9-MPA, 4-EGPA; 17 prevalence, 15 incident) had PN. Mean age±SD was 47.2±13.0 at vasculitis diagnosis. The median follow-up was 55 months (IQR 37-79) after AAV diagnosis. Main symptoms: paresthesias 97%, hypoesthesia 72%, hyporeflexia 53%, burning pain and weakness 47%, mononeuropathies 44%.

Diagnostic EMG support in 80%. The estimated incidence rate of PN was of 4/100 persons-year. Differences between cases (n=32) and controls (n=65) were smoking history (p=0.03), drug abuse (p=0.04), and a higher mean BVAS (p=0.001) at AAV diagnosis. The table shows the factors associated with a higher risk for the development of PN. After adjustment for covariates and in a multivariate analysis, a higher BVAS at baseline conferred risk for the presence of PN (HR=1.1, 95% CI 1.03-1.25, p=0.01).

Table. Risk factors for development of PN in AAV expressed as hazard ratios after Cox regression analysis.

<table>
<thead>
<tr>
<th>Variable</th>
<th>HR  (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug abuse history</td>
<td>4.34 (1.215-6)</td>
<td>0.025</td>
</tr>
<tr>
<td>Arthritis</td>
<td>2.98 (1.018-7)</td>
<td>0.04</td>
</tr>
<tr>
<td>BVAS at AAV diagnosis</td>
<td>1.13 (1.03-1.23)</td>
<td>0.005</td>
</tr>
</tbody>
</table>

Conclusion: The risk for development of PN is related to overall higher disease activity when AAV is diagnosed. However, it may not be present after many years of its appearance. We had almost the same amount of incident cases than prevalent ones at diagnosis. Therefore, patients with a highly active disease need to be followed up specifically in order to detect PN during the disease course, probably with specialized neurological evaluation.

REFERENCES


Disclosure of Interests: None declared


AB1270 EVALUATIONS OF ANTIRHEUMATIC DRUGS AT PRECONCEPTIONAL, PREGNANCY AND POSTPARTUM PERIODS OF RA PATIENTS’ IN A UNIVERSITY HOSPITAL: PRELIMINARY RESULTS

Nesrin Caglayan Duman1, Atilla Karaalp1, Nevruz Inan2, 1Marmara University, School of Medicine, Department of Pharmacology, Istanbul, Turkey; 2Marmara University, School of Medicine, Division of Rheumatology, Department of Internal Medicine, Istanbul, Turkey

Background: Rheumatoid arthritis (RA) spontaneously improves during pregnancy and disease activity decreases in approximately two-thirds of pregnant but this decrease does not last long and postpartum exacerbation can be seen. Conversely discontinuation of antirheumatic drug (ARD) during pregnancy may be a risk factor for exacerbation of RA. In case of preconceptional, pregnancy and postpartum (P&P&P) situations during RA treatment, current options are discontinuation of inappropriate medications and switching to appropriate ones. With the latest BSR and EULAR guidelines on prescribing drugs in P&P&P, treatment options expanded with some of the biologic drugs.

Objectives: The aim of this study is to analyse alterations of ARD use (discontinuation, increasing or switching) at P&P&P periods of RA patients’ retrospectively between 2002-2018.

Methods: In our records there are 25 cases of 19 female RA patients who having at least one pregnancy experienced out of 140 RA patients. The data were collected by telephone calls and patient file. Female patients that had no pregnancies after the RA diagnosis were not included. Preconception period was defined as 1 year before estimated last menstrual date. Postpartum period was defined as 1 year after infants’ birth.

Results: RA patients participating in our study of 140 female (age median 55 (26-87)), 121 of them (86%) did not give birth after the RA diagnosis. 19 of them (age median 39 (26-61)) had been pregnant after the RA diagnosis (%14) and 14 of them gave birth 1, 4 of them gave birth to 2, one of them gave birth to 3. Twelve out of 140 (9%) patients had postnatal diagnosis. Each of the pregnancies counted as one case to some female patients represented in our data more than ones. While 22 of cases used the ARD before pregnancy (88%), it decreased 18 of